Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
The Trump administration wants to reshape how the FDA funds drug reviews by tying fee discounts to U.S.-based clinical trials. Proposed changes would cut new drug application fees in half for companies conducting early-stage trials on American soil. The moves are part of a broader push to reshore pharmaceutical development away from China, though some provisions face political headwinds in Congress.
The Trump administration is weaving its "America First" agenda into the renewal of the FDA's user fee system — the mechanism that funds the agency's review of new medicines. Under proposed changes published in the Federal Register, companies that include data from at least one early-stage U.S.-based clinical trial (conducted after Oct. 1, 2027) would see their new drug application fees cut in half. Additional discounts would apply to orphan drug applications seeking a second indication, while fee waivers for small businesses would be restricted to U.S.-based companies only.
The proposals are part of a broader five-year reauthorization package that Congress must pass before the current user fee agreements expire in September 2027. The FDA and industry groups like PhRMA and the Biotechnology Innovation Organization have been in negotiations since early this year. The effort also ties into "Operation TrialBlazer," an initiative aimed at reversing the trend of early-stage clinical research moving overseas, particularly to China.
By the Numbers:
Why it matters: Reshoring drug development could reduce U.S. dependence on foreign supply chains, but tying financial incentives to trial location injects politics into what has historically been a bipartisan process — raising questions about whether science or geography will drive drug development decisions.
